Editorial
doi: 10.1001/jama.2018.0153.
Screening for Prostate Cancer: Is the Third Trial the Charm?
Affiliations
- PMID: 29509848
- DOI: 10.1001/jama.2018.0153
Item in Clipboard
Editorial
Screening for Prostate Cancer: Is the Third Trial the Charm?
JAMA.
.
Erratum in
-
Incorrect Age Range.JAMA. 2018 Apr 10;319(14):1510. doi: 10.1001/jama.2018.3290. JAMA. 2018. PMID: 29541771 No abstract available.
No abstract available
Comment on
-
Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.JAMA. 2018 Mar 6;319(9):883-895. doi: 10.1001/jama.2018.0154. JAMA. 2018. PMID: 29509864 Free PMC article. Clinical Trial.
Similar articles
-
Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer.J Urol. 2005 Feb;173(2):441. doi: 10.1097/01.ju.0000148855.17830.97. J Urol. 2005. PMID: 15643197 No abstract available.
-
General practitioner (GP)'s view on screening for prostate cancer in the Netherlands: the impact of a randomized trial.BJU Int. 2013 Jul;112(1):4-5. doi: 10.1111/bju.12078. BJU Int. 2013. PMID: 23759003 No abstract available.
-
Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?Arch Pathol Lab Med. 2013 Mar;137(3):308-9. doi: 10.5858/arpa.2012-0241-ED. Epub 2012 Jul 16. Arch Pathol Lab Med. 2013. PMID: 22799565 No abstract available.
-
Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis.Radiol Clin North Am. 2018 Mar;56(2):187-196. doi: 10.1016/j.rcl.2017.10.002. Epub 2017 Nov 26. Radiol Clin North Am. 2018. PMID: 29420975 Review.
-
Prostate cancer screening.Investig Clin Urol. 2017 Jul;58(4):217-219. doi: 10.4111/icu.2017.58.4.217. Epub 2017 Jun 20. Investig Clin Urol. 2017. PMID: 28681029 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
